• Would You Share Your Info with an MS App?
  • Results of Phase 3 Trial for Celgene’s Ozanimod Suggest Therapeutic Benefit in RMS Patients
  • Brain IFN-gamma Drives MS Disease Processes, Russian Immune Factor Analysis Finds
  • A Walk in the Park Reminds Me That I Am Not Alone
  • MS News that Caught My Eye: Risk Factors, Biotin and Symptoms, Pills, Shots or IVs, and More
  • US Blacks, Hispanics Less Likely to Get Neurological Care in Doctor’s Offices and Clinics
  • Real-world Spanish Study Confirms Gilenya’s Ability to Reduce Multiple Sclerosis Relapses
  • An MS Garden Grows in Derby
  • Phase 3 Study of High-Dose Biotin, MD1003, in Treating Primary and Secondary MS Patients Underway
  • Pilot Study of myMS App, Created to Aid Patients and Research, Starting in US
  • Defining Resiliency in MS and Ideas on Bouncing Back
  • Ocrevus Market Entry Already Changing Dynamics in MS Treatment Choices, Spherix Analysis Suggests